Caplacizumab
Chemical compound
From Wikipedia, the free encyclopedia
Caplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura.[4][6][7] It is a von Willebrand factor-directed antibody fragment.[4] It is given via intravenous injection followed by subcutaneous injection.[4] Caplacizumab was developed by Ablynx NV.
| Monoclonal antibody | |
|---|---|
| Type | Single domain antibody |
| Source | Humanized |
| Target | von Willebrand factor (VWF) |
| Clinical data | |
| Trade names | Cablivi |
| Other names | ALX-0081, caplacizumab-yhdp |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1213H1891N357O380S10 |
| Molar mass | 27876.19 g·mol−1 |
Caplacizumab was authorized for medical use in the European Union in August 2018,[5] and approved for medical use in the United States in February 2019.[8][9] The US Food and Drug Administration considers it to be a first-in-class medication.[10]
Medical uses
Caplacizumab is indicated for the treatment of acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy.[4][5][11]
Side effects
Common adverse effects include injection site reactions, reported in 3–6% of patients in the HERCULES and TITAN trials.[12]
Society and culture
Legal status
Caplacizumab was authorized for medical use in the European Union in August 2018,[5] and approved for medical use in the United States in February 2019.[8][11]
Economics
The cost-effectiveness has been questioned.[13]
Names
Caplacizumab is the international nonproprietary name[14] and the United States Adopted Name.[15]
Research
Use of caplacizumab without plasmapheresis has been reported.[16] The MAYARI study was designed to evaluate the effectiveness of this option.[17]
